Author: admin

Pest Brothers, Inc. Educates Homestead, FL on the Top Pests Included in Their General Treatment Services

“Ants”
Discover which pests are covered under Pest Brothers, Inc.’s general treatment program in Homestead, FL. Learn how their licensed technicians keep your home pest-free.

Homestead, FL – In an effort to help residents better understand what pests are covered under their general treatment services, Pest Brothers, Inc., a licensed and insured provider of pest, lawn, and termite control, is educating the Homestead, FL community on the most common household pests they encounter—and how their team addresses them.

Homeowners often face confusion about which pests are included in their service plans and which require additional treatment. Pest Brothers, Inc. is working to close this knowledge gap by highlighting the pests included in their core pest control Homestead program, giving residents the clarity they need when choosing a reliable and effective pest protection solution.

Common Pests Included in the General Treatment Program

Pest Brothers, Inc.’s general pest control Homestead FL services are designed to offer comprehensive protection from many of the most common crawling insects and nuisance pests found in Florida homes. Their standard treatment plan includes ants, spiders, beetles, silverfish, centipedes, millipedes, and other general household invaders. On request, and when necessary, their team also applies treatment for wasps, hornets, bees, and yellow jackets.

The general pest control process starts with a full inspection and focuses on both the interior and exterior of the home. Licensed technicians identify problem areas, entry points, and nesting zones. Interior treatments, which include baiting kitchen and bathroom plumbing access points as well as garage treatment, are offered as part of the initial service or when specific issues arise. Exterior barrier treatments are performed on a scheduled basis—monthly, every other month, or quarterly—depending on the customer’s needs.

What’s Not Included but Available Separately

While the Homestead pest control plan covers a wide range of insects, it does not include lawn pests, German cockroach clean-outs, mosquitoes, termites, rodents, or wildlife services—though these can all be purchased separately. Bed bugs and imported fire ants also fall outside of the general plan but are treated through targeted, professional services using safe and effective methods.

This clarification ensures that customers receive tailored recommendations and realistic expectations. Pest Brothers, Inc. emphasizes transparency and education as part of their customer-first philosophy, which helps homeowners feel confident and informed about their pest protection plan.

Safety-First, Year-Round Protection

Treatments are designed with the safety of families and pets in mind, using environmentally friendly and safe pesticides. Pest Brothers, Inc. employs Integrated Pest Management (IPM) techniques to prevent infestations, limit the use of pesticides, and maintain long-term pest-free environments. Their service program includes call-backs as needed to ensure customer satisfaction between scheduled visits.

About Pest Brothers, Inc. – Pest, Lawn, & Termite Control

Pest Brothers, Inc. is a pest control company in Homestead, FL that offers a full suite of pest control services across Florida. Founded by two brothers with extensive backgrounds in pest management and business operations, the company is known for its quick response times, customer-focused service, and high-quality results. Their services include general pest control, termite treatments, mosquito programs, rodent and wildlife control, lawn care, and more.

With a strong presence in Homestead, Pest Brothers, Inc. remains committed to protecting homes and businesses through proactive, professional, and reliable pest control solutions.

Media Contact
Company Name: Pest Brothers, Inc. – Pest, Lawn, & Termite Control
Contact Person: Jose & Michael Rodriguez
Email: Send Email
Phone: 786-564-1163
City: Maimi
State: Florida
Country: United States
Website: https://pestbros.net/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pest Brothers, Inc. Educates Homestead, FL on the Top Pests Included in Their General Treatment Services

“Going Public” Season 3 Announces Dutch Mendenhall, CEO of Omnico Golf, as Featured Founder

Tampa, Florida – May 15th, 2025 – The hit interactive series “Going Public” returns for its highly touted third season, featuring a new group of groundbreaking startups and cutting-edge investors. This season welcomes Dutch Mendenhall, Omnico Golf founder. He has sharp business acumen and an entrepreneurial emphasis on cutting-edge asset operations, along with Jesse Tinsley and Joelle Weinand.

“Going Public” is the franchise that alone allows viewers to invest in companies being showcased on the program in real-time as they air. The show provides viewers a front-row seat to entrepreneurship, stopping short of grit, strategy, and striving for public market triumph. Season 3 raises the stakes by adding Mendenhall, revenue operations leader for golf courses and associated assets, who joins the investor panel to assess, advise, and invest in featured founders.

“Entrepreneurship is the backbone of economic freedom,” said Mendenhall. “I’m excited to be part of Going Public Season 3 and help spotlight companies bold enough to chase the public markets. We’re not just investing capital—we’re investing in people and vision.”

Mendenhall leads Omnico Golf as CEO while transforming the golf industry through technological operations and strategic business acquisitions. The Season 3 participant Jesse Tinsley of Employer.com joins Mendenhall as well as Joelle Weinand of Nutcase Foods to note that the season focuses on achieving real traction and global vision. The founders at Nutcase Foods felt honored to receive the selection because they combined traditional chocolate milk with healthier ingredients. These leaders demonstrate innovative approaches to building public companies while showing ambition for the future.

“Season 3 of Going Public isn’t just about raising capital, it’s about raising the bar. I’m honored to represent Employer.com and show what it looks like when real traction, bold leadership, and global vision come together. This season’s companies embody what it truly means to build in public,” stated Jesse Tinsley, the Founder ofEmployer.com

“We were pumped to have been selected to be on Going Public and share our story on X. Allowing fans and viewers to get in early and own a piece of Nutcase,” stated Joelle Weinand, NutCase Foods Founder. “Nutcase brilliantly combines the nostalgic appeal of chocolate milk with a premium, better-for-you, beverage in sleek packaging that is simultaneously sophisticated enough for the boardroom and edgy enough for EDM festivals. Something that kids and adults love and will be a game-changer on the show!”

The new season is live and underway, streaming exclusively globally on X. The audience will witness a new generation of founders living it all, finding growth, fundraising, and their way to going public, and being motivated to become early investors in the process themselves.

For press inquiries or additional information, please contact Thomas Mustac, Otter PR Senior Publicist, at thomas.mustac@otterpr.com or visit https://www.omnicogolf.com/

About Going Public

Going Public is an entrepreneurial show in which audiences have the opportunity to invest in the businesses featured on the program. Each season profiles up-and-coming companies and the investors behind them as they raise capital from the public and mature toward IPOs. Crush Capital produces the series and syndicates globally.

About Dutch Mendenhall & Omnico Golf

Dutch Mendenhall serves as CEO and founder of Omnico Golf, the golf course strategic ownership and revenue management market leader, and its related assets. An advocate for alternative asset classes.

Media Contact
Company Name: OtterPR
Contact Person: Thomas Mustac
Email: Send Email
Address:320 1st Ave N
City: St. Petersburg
State: Florida
Country: United States
Website: OtterPR.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: “Going Public” Season 3 Announces Dutch Mendenhall, CEO of Omnico Golf, as Featured Founder

IAOTP Unveils “Top 50 Fearless Leaders Volume 4,” Continuing the Global Leadership Legacy

The International Association of Top Professionals (IAOTP) announces the highly anticipated release of “Top 50 Fearless Leaders Volume 4,” set to launch on May 28, 2025, following the remarkable success of the previous three volumes, which topped bestseller lists worldwide.

The International Association of Top Professionals (IAOTP) is poised to elevate its influential leadership series with the release of “Top 50 Fearless Leaders Volume 4,” scheduled for May 28, 2025. The latest volume in the bestselling series continues IAOTP’s mission of spotlighting transformative leaders whose stories of resilience, innovation, and purpose inspire readers across the globe.

Building on the critical acclaim of the previous three volumes, “Top 50 Fearless Leaders Volume 4” assembles another cohort of exceptional leaders whose personal and professional journeys embody the essence of fearless leadership. Each story delves into the challenges faced and the lessons learned, offering readers actionable insights and powerful narratives that underscore the impact of visionary leadership in today’s evolving landscape.

Stephanie Cirami, President and Founder of IAOTP and Editor-in-Chief of TIP Magazine, has once again curated a compelling collection of leaders from diverse industries, ensuring a broad spectrum of experiences and expertise is represented.

“In Volume 4, we continue our commitment to showcasing leaders who redefine what it means to lead with purpose and passion,” Cirami said. “These individuals not only excel in their respective fields but also inspire others to strive for excellence and make a meaningful impact in their communities. Their stories are not just about success; they are about resilience, vision, and the courage to break barriers.”

Previous volumes of “Top 50 Fearless Leaders” have reached the top of bestseller lists in multiple countries, further establishing the series as a trusted source of leadership inspiration and strategic insights. This newest installment is expected to expand on that legacy, offering readers a fresh perspective on leadership challenges and opportunities in a rapidly shifting global landscape.

“Top 50 Fearless Leaders Volume 4” will be available on Kindle for a special introductory price of $0.99, reaffirming IAOTP’s dedication to making leadership wisdom accessible to a broad audience. A print edition is also set to follow later in the summer, allowing readers to explore these powerful stories in multiple formats.

The International Association of Top Professionals continues to be a driving force in recognizing and amplifying the voices of influential leaders around the world. With a highly selective membership process, IAOTP brings together top professionals committed to excellence, innovation, and inspiring future generations.

Media Contact
Company Name: Metrix Promotions
Contact Person: Barak Granot
Email: Send Email
Phone: 18006515818
Country: United States
Website: https://www.iaotp.com/

Hodgkin’s Lymphoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Hodgkin’s Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Hodgkin’s Lymphoma pipeline landscape. It covers the Hodgkin’s Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hodgkin’s Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hodgkin’s Lymphoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Hodgkin’s Lymphoma Pipeline Outlook

Key Takeaways from the Hodgkin’s Lymphoma Pipeline Report

  • In May 2025, Celgene announced a phase II study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma.
  • In May 2025, Hoffmann-La Roche conducted a Phase I/II study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab.
  • In May 2025, Bristol-Myers Squibb organized a study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
  • DelveInsight’s Hodgkin’s Lymphoma Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hodgkin’s Lymphoma treatment.
  • The leading Hodgkin’s Lymphoma Companies such as Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others.
  • Promising Hodgkin’s Lymphoma Pipeline Therapies such as HCD122, Resminostat (4SC-201), Ruxolitinib, AK105, ITF2357, Panobinostat, Obatoclax mesylate (GX15-070MS) and others.

Stay ahead with the most recent pipeline outlook for Hodgkin’s Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hodgkin’s Lymphoma Treatment Drugs

Hodgkin’s Lymphoma Emerging Drugs Profile

  • AFM 13: Affimed Therapeutics

AFM13 is a first-in-class innate cell engager (ICE®) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. AFM13 is most advanced ICE® clinical program and was evaluated as monotherapy in a Phase IIB trial in patients with relapsed/refractory peripheral T cell lymphoma (REDIRECT). The study achieved an ORR of 32.4% demonstrating anti-tumor activity with a DOR of 2.3 months and a well-managed safety profile. AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells and the tumor creating the necessary proximity for the innate immune cells to specifically destroy the tumor cells. Currently it is in Phase II stage of clinical trial evaluation to treat Hodgkin’s Lymphoma.

  • AUR105 : Aurigene Oncology

AUR105 is a small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). The drug candidate is also under development for other indications like solid tumor, non-Hodgkin lymphoma, leukemia or Hodgkin lymphoma. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I for the treatment of Hodgkin’s Lymphoma.

The Hodgkin’s Lymphoma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Hodgkin’s Lymphoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hodgkin’s Lymphoma Treatment.
  • Hodgkin’s Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Hodgkin’s Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hodgkin’s Lymphoma market

Explore groundbreaking therapies and clinical trials in the Hodgkin’s Lymphoma Pipeline. Access DelveInsight’s detailed report now! @ New Hodgkin’s Lymphoma Drugs

Hodgkin’s Lymphoma Companies

Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others.

Hodgkin’s Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical

Hodgkin’s Lymphoma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Unveil the future of Hodgkin’s Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Hodgkin’s Lymphoma Market Drivers and Barriers

Scope of the Hodgkin’s Lymphoma Pipeline Report

  • Coverage- Global
  • Hodgkin’s Lymphoma Companies- Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others.
  • Hodgkin’s Lymphoma Pipeline Therapies- HCD122, Resminostat (4SC-201), Ruxolitinib, AK105, ITF2357, Panobinostat, Obatoclax mesylate (GX15-070MS) and others.
  • Hodgkin’s Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hodgkin’s Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Hodgkin’s Lymphoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Hodgkin’s Lymphoma Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Hodgkin’s Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Hodgkin’s Lymphoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug Name: Company Name
  9. Drug profiles in the detailed report…..
  10. Mid-Stage Products (Phase II)
  11. AFM13: Affimed Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AUR105 : Aurigene Oncology
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Hodgkin’s Lymphoma Key Companies
  21. Hodgkin’s Lymphoma Key Products
  22. Hodgkin’s Lymphoma- Unmet Needs
  23. Hodgkin’s Lymphoma- Market Drivers and Barriers
  24. Hodgkin’s Lymphoma- Future Perspectives and Conclusion
  25. Hodgkin’s Lymphoma Analyst Views
  26. Hodgkin’s Lymphoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hodgkins-lymphoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hodgkin’s Lymphoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Relapsed/refractory acute myeloid leukemia Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Relapsed/Refractory Acute Myeloid Leukemia Pipeline. Dive into DelveInsight’s comprehensive report today! @ Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook

Key Takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report

  • In May 2025, ARCE Therapeutics Inc. announced a study is ARD103, a C-type lectin-like molecule-1 (CLL-1) autologous chimeric antigen receptor T-cells (CAR-T). CLL-1 is highly expressed on both myeloid blasts and leukemia stem cells (LSCs) but is absent on normal hematopoietic stem cells (HSCs), suggesting CLL-1 as an excellent therapeutic target for AML and hence other potential myeloid malignancies.
  • In May 2025, Vor Biopharma announced a Phase 1/2 study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).
  • In May 2025, Apollo Therapeutics Ltd conducted a phase 1/2 study to determine the safety, tolerability, and efficacy of APL-4098 alone and/or in combination with azacitidine for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)/AML and MDS-excess blasts (EB). Participants with the MDS-EB subtype will be eligible for the Phase 1 part of the study only.
  • DelveInsight’s Relapsed/Refractory Acute Myeloid Leukemia Pipeline report depicts a robust space with 50+ active players working to develop 75+ pipeline therapies for Relapsed/Refractory Acute Myeloid Leukemia treatment.
  • The leading Relapsed/Refractory Acute Myeloid Leukemia Companies such as Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen and others.
  • Promising Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapies such as APG-2575, Cytarabine, Venetoclax, Tagraxofusp, Cladribine (CLAD), Venetoclax Oral Tablet, Selinexor, Idarubicin and others.

Stay ahead with the most recent pipeline outlook for Relapsed/Refractory Acute Myeloid Leukemia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Relapsed/Refractory Acute Myeloid Leukemia Treatment Drugs

Relapsed/Refractory Acute Myeloid Leukemia Emerging Drugs Profile

  • APG-2575: Ascentage Pharma

APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma. It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis. , to achieve the purpose of tumor treatment. APG-2575 is the first locally developed Bcl-2 selective inhibitor to enter clinical stage in China. APG-2575 has been granted orphan drug designation by the US FDA for five indications (Indications: refractory chronic lymphocytic leukemia CLL, multiple myeloma, Waldenström macroglobulinemia, acute myeloid leukemia, follicular lymphoma).

  • CLN 049: Cullinan Oncology

CLN-049 (Florentine) is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML or MDS.

  • Lanraplenib: Kronos Bio

Lanraplenib, is a next-generation SYK inhibitor that has previously been studied as a potential treatment for autoimmune diseases. In preclinical studies, Lanraplenib was shown to have anti-leukemic activity against NPM1-mutated and FLT3-mutated AML samples. Lanraplenib, is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/orFLT3-mutated AML who are older than 75 years old or are not eligible for intensive induction chemotherapy.

The Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Relapsed/Refractory Acute Myeloid Leukemia with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsed/Refractory Acute Myeloid Leukemia Treatment.
  • Relapsed/Refractory Acute Myeloid Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Relapsed/Refractory Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsed/Refractory Acute Myeloid Leukemia market

Explore groundbreaking therapies and clinical trials in the Relapsed/Refractory Acute Myeloid Leukemia Pipeline. Access DelveInsight’s detailed report now! @ New Relapsed/Refractory Acute Myeloid Leukemia Drugs

Relapsed/Refractory Acute Myeloid Leukemia Companies

Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen and others.

Relapsed/refractory acute myeloid leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Relapsed/Refractory Acute Myeloid Leukemia Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Unveil the future of Relapsed/Refractory Acute Myeloid Leukemia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Barriers

Scope of the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report

  • Coverage- Global
  • Relapsed/Refractory Acute Myeloid Leukemia Companies- Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen and others.
  • Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapies- APG-2575, Cytarabine, Venetoclax, Tagraxofusp, Cladribine (CLAD), Venetoclax Oral Tablet, Selinexor, Idarubicin and others.
  • Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Relapsed/Refractory Acute Myeloid Leukemia Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Relapsed/Refractory Acute Myeloid Leukemia Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Relapsed/refractory acute myeloid leukemia (AML): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Relapsed/refractory acute myeloid leukemia (AML)– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase I/II)
  11. APG-2575: Ascentage Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. CLN 049: Cullinan Oncology
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
  21. Relapsed/refractory acute myeloid leukemia (AML) Key Products
  22. Relapsed/refractory acute myeloid leukemia (AML)- Unmet Needs
  23. Relapsed/refractory acute myeloid leukemia (AML)- Market Drivers and Barriers
  24. Relapsed/refractory acute myeloid leukemia (AML)- Future Perspectives and Conclusion
  25. Relapsed/refractory acute myeloid leukemia (AML) Analyst Views
  26. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Relapsed/Refractory Acute Myeloid Leukemia Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Non-Cystic Fibrosis Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Non‐cystic fibrosis bronchiectasis Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Non‐cystic fibrosis bronchiectasis pipeline landscape. It covers the Non-Cystic Fibrosis Bronchiectasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Cystic Fibrosis Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Non-Cystic Fibrosis Bronchiectasis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Non-Cystic Fibrosis Bronchiectasis Pipeline Outlook

Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report

  • In May 2025, Jiangsu HengRui Medicine Co., Ltd. announced a study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis.
  • In May 2025, Genentech Inc. conducted a study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in patients with muco-obstructive disease.
  • DelveInsight’s Non-Cystic Fibrosis Bronchiectasis Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Non-Cystic Fibrosis Bronchiectasis treatment.
  • The leading Non-Cystic Fibrosis Bronchiectasis Companies such as Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
  • Promising Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies such as Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, Ciprofloxacin DPI (BAYQ3939) and others.

Stay ahead with the most recent pipeline outlook for Non-Cystic Fibrosis Bronchiectasis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non-Cystic Fibrosis Bronchiectasis Treatment Drugs

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs Profile

  • Brensocatib: Insmed Incorporated

Brensocatib (INS1007 or AZD7986) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation.

  • HSK31858: Haisco Pharmaceutical Group Co., Ltd.

HSK31858 tablet is an oral, potent, and highly selective dipeptidyl peptidase 1 (DPP1) small molecule inhibitor independently developed by the Haisco Pharmaceutical. The main mechanism of action is that inhibiting DPP1 can inhibit the activation of neutrophils and the release of neutrophils to the circulatory system by inhibiting the activation of neutrophil NSP enzymes. It is clinically intended to be used for the treatment of lower respiratory tract diseases caused by bronchiectasis and acute lung injury/acute respiratory distress syndrome. The drug has completed phase I clinical trials in Australia and China, and now the phase II clinical trials of the project have completed the enrollment and administration of the first subject, and the project is progressing smoothly.

  • CSL 787: CSL Behring

CSL 787, is a human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non‐cystic fibrosis bronchiectasis (NCFB). Currently, the drug is being developed in the Phase I stage of Clinical trial evaluation for the treatment of Non‐cystic fibrosis bronchiectasis.

The Non-Cystic Fibrosis Bronchiectasis Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment.
  • Non-Cystic Fibrosis Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Non-Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market

Explore groundbreaking therapies and clinical trials in the Non-Cystic Fibrosis Bronchiectasis Pipeline. Access DelveInsight’s detailed report now! @ New Non-Cystic Fibrosis Bronchiectasis Drugs

Non-Cystic Fibrosis Bronchiectasis Companies

Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.

Non‐cystic fibrosis bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Unveil the future of Non-Cystic Fibrosis Bronchiectasis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers

Scope of the Non-Cystic Fibrosis Bronchiectasis Pipeline Report

  • Coverage- Global
  • Non-Cystic Fibrosis Bronchiectasis Companies- Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
  • Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies- Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, Ciprofloxacin DPI (BAYQ3939) and others.
  • Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Non-Cystic Fibrosis Bronchiectasis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Non-Cystic Fibrosis Bronchiectasis Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Non‐cystic fibrosis bronchiectasis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non‐cystic fibrosis bronchiectasis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Brensocatib: Insmed Incorporated
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. HSK31858: Haisco Pharmaceutical Group Co., Ltd.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. CSL 787: CSL Behring
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Non‐cystic fibrosis bronchiectasis Key Companies
  21. Non‐cystic fibrosis bronchiectasis Key Products
  22. Non‐cystic fibrosis bronchiectasis- Unmet Needs
  23. Non‐cystic fibrosis bronchiectasis- Market Drivers and Barriers
  24. Non‐cystic fibrosis bronchiectasis- Future Perspectives and Conclusion
  25. Non‐cystic fibrosis bronchiectasis Analyst Views
  26. Non‐cystic fibrosis bronchiectasis Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Cystic Fibrosis Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

CDK7 Inhibitors Market Set for Robust Growth Through 2034, Driven by Innovative Pipeline, Strategic Collaborations, and Expanding Oncology Applications | DelveInsight

“CDK7 Inhibitors Market Size, Target Population, Competitive Landscape and Market Forecast – DelveInsight”
The CDK7 inhibitors market is projected to experience substantial growth through 2034, driven by a robust pipeline of novel agents, a growing understanding of CDK7’s role in cancer biology, and a growing patient pool. Leading pharmaceutical companies, including Carrick, Pfizer, Menarini Group, Roche, Qurient, Merck, Arvinas, Syros Pharmaceuticals, and others, are at the forefront of developing novel CDK7-targeted therapies that promise to address significant unmet needs in oncology treatment.

DelveInsight’s “CDK7 Inhibitors Market Size, Target Population, Competitive Landscape and Market Forecast – 2034” report provides comprehensive insights into the evolving CDK7 inhibitors market across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. The report details existing treatment practices, emerging therapies, market dynamics, and competitive landscape in the CDK7 inhibitor landscape.

The CDK7 inhibitors market is poised for remarkable expansion through 2034, driven by a robust pipeline of novel agents, a growing understanding of CDK7’s pivotal role in cancer biology, and a growing addressable patient pool, particularly in malignancies characterized by resistance to standard therapies. As the oncology community intensifies its focus on precision medicine and targeted therapies, CDK7 inhibitors are emerging as a transformative class, promising to reshape the treatment landscape for several hard-to-treat cancers.

Download the CDK7 Inhibitors Market Forecast Report to understand which factors are driving the CDK7 Inhibitors market @ CDK7 Inhibitors Market Trends.

Cyclin-dependent kinase 7 inhibitors stand out due to their dual mechanism of action. They regulate both cell cycle progression and transcription, two processes frequently hijacked by cancer cells. CDK7 acts as a master regulator by activating other cyclin-dependent kinases, including CDK1, CDK2, CDK4, and CDK6, and by phosphorylating RNA polymerase II, which is essential for transcription initiation. This unique positioning enables CDK7 inhibitors to simultaneously disrupt aberrant cell division and transcriptional addiction in tumor cells, leading to potent antitumor effects.

The epidemiological landscape further supports the market’s growth trajectory. The total incident population of HR+/HER2- breast cancer in the 7MM was nearly 480K cases in 2023, and this number is expected to rise steadily through 2034. The high prevalence of cancers with elevated CDK7 expression, coupled with the urgent need for therapies that can overcome resistance to existing treatments, is fueling demand for CDK7 inhibitors. These agents are particularly attractive for patients with advanced disease who have exhausted standard options, as well as for those with aggressive tumor subtypes, such as triple-negative breast cancer and small cell lung cancer.

Discover evolving trends in the CDK7 Inhibitors patient pool forecasts @ CDK7 Inhibitors Epidemiological Analysis.

The CDK7 inhibitors market is rapidly evolving, with leading pharmaceutical companies such as Carrick Therapeutics (LSE: CRK), Pfizer (NYSE: PFE), Menarini Group (BIT: MRN), Roche (SIX: ROG), Qurient (KOSDAQ: QURT), Merck Sharp & Dohme (NYSE: MRK), Arvinas (NASDAQ: ARVN), and Syros Pharmaceuticals (NASDAQ: SYRS), among others, spearheading the development of selective CDK7-targeted agents.

Among the leading clinical-stage candidates is Samuraciclib, developed by Carrick Therapeutics (NASDAQ: CTRX), which is currently the leading oral CDK7 inhibitor in clinical development. Samuraciclib’s primary indication is HR+/ HER2- breast cancer, but its potential extends to multiple other solid and hematologic malignancies. Early clinical studies have shown a favorable safety profile and encouraging efficacy, prompting the FDA to grant Fast Track designation for samuraciclib in combination with fulvestrant for CDK4/6 inhibitor-resistant HR+/ HER2- advanced breast cancer, as well as in combination with chemotherapy for locally advanced or metastatic triple-negative breast cancer.

Qurient’s Q901 is another promising CDK7 inhibitor, currently under evaluation, is being studied in combination with an antibody-drug conjugate targeting TROP2 for the treatment of small cell lung cancer and other relapsed solid tumors. The clinical trial, QRNT-009, has demonstrated robust tumor growth inhibition in preclinical models of HR+ breast cancer, pancreatic cancer, prostate cancer, ovarian cancer, and small cell lung cancer, both as a monotherapy and in combination with other agents. A Phase I/II study (NCT05394103) is underway to determine the maximum tolerated dose, safety profile, and anticancer efficacy.

Syros Pharmaceuticals has also made significant strides, receiving a patent in April 2024 for compounds that selectively inhibit CDK7, inducing cellular apoptosis and inhibiting transcription. This intellectual property milestone underscores the innovation and competitive intensity within the CDK7 inhibitor space, as companies race to bring first-in-class or best-in-class agents to market.

Discover evolving trends in the CDK7 Inhibitors treatment landscape @ CDK7 Inhibitors Recent Developments.

Despite these promising developments, the CDK7 inhibitors market faces challenges, including the need to optimize selectivity to minimize off-target effects, manage potential toxicity due to CDK7’s role in normal cellular processes, and address the emergence of resistance mechanisms. Nonetheless, the ongoing integration of biomarker-driven approaches and combination strategies is expected to enhance the efficacy and safety profiles of these agents, paving the way for their incorporation into standard-of-care regimens.

Looking ahead, the CDK7 inhibitors market in the 7MM is expected to witness significant growth through 2034, driven by the launch of innovative therapies, expanding clinical indications, and the increasing adoption of personalized medicine in oncology. The competitive landscape will continue to evolve as more companies enter the field and as ongoing trials yield pivotal data. As CDK7 inhibitors advance toward regulatory approval and commercialization, they are set to offer new hope for patients with difficult-to-treat cancers and to establish themselves as a cornerstone of future cancer therapy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of CDK 7 Inhibitors

4. Key Events

5. CDK 7 Inhibitors Market Overview At A Glance

6. Background And Overview

7. CDK 7 inhibitors Target Population

8. CDK 7 Inhibitors Marketed Drugs

9. CDK 7 Inhibitors Emerging Drugs

10. CDK 7 Inhibitors Market: The 7MM Analysis

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. CDK 7 Inhibitors Market Access and Reimbursement

15. Appendix

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CDK7 Inhibitors Market Set for Robust Growth Through 2034, Driven by Innovative Pipeline, Strategic Collaborations, and Expanding Oncology Applications | DelveInsight

Interstitial Lung Diseases Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s “Interstitial Lung Diseases Pipeline Insight 2025” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Diseases pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Interstitial Lung Diseases pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Interstitial Lung Diseases Pipeline. Dive into DelveInsight’s comprehensive report today! @ Interstitial Lung Diseases Pipeline Outlook

Key Takeaways from the Interstitial Lung Diseases Pipeline Report

  • In May 2025, aTyr Pharma Inc. announced a study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1 of 2 active (experimental) dose arms or placebo, administered every 4 weeks up to and including Week 20. Part B is an optional open-label extension to Part A in which participants can receive 450 mg efzofitimod every 4 weeks for 6 doses.
  • In May 2025, Boehringer Ingelheim conducted a study is open to children and adolescents with interstitial lung disease (ILD) that causes lung fibrosis. This is a study for people who took part in a previous study called InPedILD (study 1199-0337) and for people who are between 6 and 17 years old (in France, between 12 and 17 years old) and have fibrosing ILD.
  • In May 2025, Rein Therapeutics organized a study that includes a 28-day Screening Period, a 24-week Treatment Period, and 4-week Follow-up Period. Safety and tolerability will be evaluated with the following assessments: physical examination; collection of vital sign data (heart rate, blood pressure, respiratory rate and peripheral oxygen saturation [SpO2] via pulse oximetry); heart data collected by 12-lead electrocardiogram; and collection of blood samples for safety laboratory tests.
  • In May 2025, Kadmon Corporation LLC announced a Phase 2 study is to be conducted to evaluate the safety, tolerability, and activity of 400 mg of belumosudil orally (PO) once-daily (QD) compared to Best Supportive Care (BSC) in male and postmenopausal/surgically sterilized female subjects with Idiopathic Interstitial Lung Diseases (IPF).
  • In May 2025, Bristol-Myers Squibb announced a phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Interstitial Lung Diseases.
  • DelveInsight’s Interstitial Lung Diseases Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Interstitial Lung Diseases treatment.
  • The leading Interstitial Lung Diseases Companies such as Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences and others.
  • Promising Interstitial Lung Diseases Pipeline Therapies such as Dotarem, efzofitimod 450 mg, Fentanyl Citrate, Belimumab, Nintedanib (Ofev®), Anlotinib, Pirfenidone, BI 1015550, Bosentan, Mycophenolate mofetil, Cyclophosphamide and others.

Stay ahead with the most recent pipeline outlook for Interstitial Lung Diseases. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Interstitial Lung Diseases Treatment Drugs

Interstitial Lung Diseases Emerging Drugs Profile

  • DWN12088: Daewoong Pharmaceutical

DWN12088 is an investigational therapy for idiopathic Interstitial Lung Diseases (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body’s ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein’s sequence. The FDA designated it as an orphan drug for idiopathic Interstitial Lung Diseases (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.

  • LYT-100: PureTech

LYT-100 is PureTech’s most advanced wholly-owned therapeutic candidate. A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., IPF and potentially other PF-ILDs and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema. PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested. PureTech is evaluating LYT-100 in a Phase 2 trial as a potential treatment for Long COVID respiratory complications and related sequelae as well as in a Phase 2a proof-of-concept study in patients with breast cancer-related, upper limb secondary lymphedema. PureTech is also advancing LYT-100 for the treatment of IPF and potentially other PF-ILDs and is planning registration-enabling studies. PureTech also expects to initiate a Phase 2 dose-ranging trial of LYT-100 in patients with IPF in the first half of 2022.

  • BMS-986278: Bristol-Myers Squibb

BMS 986278, a lysophosphatidic acid receptor antagonist (LPA1) is being developed by Bristol-Myers Squibb, the treatment of idiopathic Interstitial Lung Diseases. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. Currently, it is in Phase II stage of clinical trial evaluation.

The Interstitial Lung Diseases Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Lung Diseases with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Lung Diseases Treatment.
  • Interstitial Lung Diseases Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Interstitial Lung Diseases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Lung Diseases market

Explore groundbreaking therapies and clinical trials in the Interstitial Lung Diseases Pipeline. Access DelveInsight’s detailed report now! @ New Interstitial Lung Diseases Drugs

Interstitial Lung Diseases Companies

Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences and others.

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous

Interstitial Lung Diseases Products have been categorized under various Molecule types such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Unveil the future of Interstitial Lung Diseases Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Interstitial Lung Diseases Market Drivers and Barriers

Scope of the Interstitial Lung Diseases Pipeline Report

  • Coverage- Global
  • Interstitial Lung Diseases Companies- Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences and others.
  • Interstitial Lung Diseases Pipeline Therapies- Dotarem, efzofitimod 450 mg, Fentanyl Citrate, Belimumab, Nintedanib (Ofev®), Anlotinib, Pirfenidone, BI 1015550, Bosentan, Mycophenolate mofetil, Cyclophosphamide and others.
  • Interstitial Lung Diseases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Interstitial Lung Diseases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Interstitial Lung Diseases Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Interstitial Lung Diseases Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Interstitial Lung Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Interstitial Lung Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. RO-0220912: Roche
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Daratumumab: Janssen Biotech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. BGB 16673: BeiGene
  15. Drug profiles in the detailed report…..
  16. Preclinical Stage Products
  17. Drug name: Company name
  18. Inactive Products
  19. Interstitial Lung Disease Key Companies
  20. Interstitial Lung Disease Key Products
  21. Interstitial Lung Disease- Unmet Needs
  22. Interstitial Lung Disease- Market Drivers and Barriers
  23. Interstitial Lung Disease- Future Perspectives and Conclusion
  24. Interstitial Lung Disease Analyst Views
  25. Interstitial Lung Disease Key Companies
  26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Interstitial Lung Diseases Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Bronchiectasis Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Bronchiectasis Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including Bronchiectasis clinical trials and nonclinical stage products. It also covers the Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Bronchiectasis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Bronchiectasis Pipeline Outlook

Key Takeaways from Bronchiectasis Pipeline Report

  • In May 2025, Jiangsu HengRui Medicine Co., Ltd. announced a study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis.
  • In May 2025, Genentech Inc. announced a phase I study to Evaluate the Safety, Tolerability, and Activity of Inhaled GDC-6988 in Patients With Muco-Obstructive Disease.
  • In May 2025, Mannkind Corporation conducted a phase 3 study of the Efficacy and Safety of Clofazimine Inhalation Suspension When Added to Guideline-Based Therapy in Participants With Nontuberculous Mycobacterial Infection.
  • DelveInsight’s Bronchiectasis Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Bronchiectasis treatment.
  • The leading Bronchiectasis Companies such as AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others.
  • Promising Bronchiectasis Pipeline Therapies such as Clofazimine Inhalation Suspensio, Ambroxol hydrochloride 30 mg, N-acetylcysteine (NAC) 600 mg, AG1321001 (drug), EZ-2053, GDC-6988, RSS0343 Tabella and others.

Stay ahead with the most recent pipeline outlook for Bronchiectasis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Bronchiectasis Treatment Drugs

Bronchiectasis Emerging Drugs Profile

  • Benralizumab: AstraZeneca

Benralizumab is a monoclonal antibody used to treat eosinophilic asthma. Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. Currently, being evaluated in Phase III stage of clinical trial evaluation to treat Non-cystic Fibrosis Bronchiectasis.

  • S1226: SolAeroMed

S1226 formulation consists of aerosolized carbon dioxide (CO2) and nebulized perflubron; which is delivered into the lung. The delivery of this formulation results in an immediate relaxant effect on the patient’s constricted airways, supported by a lowering of surface tension in inflamed areas (resulting in enhanced bronchial dilation) and possible clearing of mucus plugs of blocked airways.The rescue treatment works on both physiological and biophysical principles offering a unique approach to relieving airway obstruction. CO2 is a potent, but short acting bronchial smooth muscle relaxant. Perflubron is a non-toxic (biocompatible) medical perfluorocarbon with mucolytic and surfactant properties that acts synergistically with CO2 to provide a much greater and more prolonged broncho-dilatory effect. The drug product is hypothesized to open constricted airways through at least three distinct mechanisms. Firstly, through the relaxant effect of CO2 (alone and dissolved into perflubron) on constricted airway smooth muscle; secondly, by lowering surface tension in the inflamed airways; and finally by possibly facilitating penetration and lubrication of mucus plugs, thus enhancing mucociliary clearance. Furthermore it works by an entirely different mechanism to the ß-adrenergic agonists and thus complements, rather than replaces, existing treatments.

  • Brensocatib: Insmed

Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs.

The Bronchiectasis Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Bronchiectasis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchiectasis Treatment.
  • Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchiectasis market

Explore groundbreaking therapies and clinical trials in the Bronchiectasis Pipeline. Access DelveInsight’s detailed report now! @ New Bronchiectasis Drugs

Pulmonary Fibrosis Companies

AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others.

Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

Bronchiectasis Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

Unveil the future of Bronchiectasis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Bronchiectasis Market Drivers and Barriers

Scope of the Bronchiectasis Pipeline Report

  • Coverage- Global
  • Bronchiectasis Companies- AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others.
  • Bronchiectasis Pipeline Therapies- Clofazimine Inhalation Suspensio, Ambroxol hydrochloride 30 mg, N-acetylcysteine (NAC) 600 mg, AG1321001 (drug), EZ-2053, GDC-6988, RSS0343 Tabella and others.
  • Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Bronchiectasis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Bronchiectasis Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Bronchiectasis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Bronchiectasis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Benralizumab: AstraZeneca
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. S1226: SolAeroMed
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. CSL787: CSL Behring
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. AP-PA02: Armata Pharmaceuticals
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Bronchiectasis Key Companies
  21. Bronchiectasis Key Products
  22. Bronchiectasis- Unmet Needs
  23. Bronchiectasis- Market Drivers and Barriers
  24. Bronchiectasis- Future Perspectives and Conclusion
  25. Bronchiectasis Analyst Views
  26. Bronchiectasis Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bronchiectasis Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Non-Postoperative Acute Pain Market Poised for Significant Expansion by 2034, Amid FDA Approvals and Innovative Therapeutic Pipeline | DelveInsight

“Non-Postoperative Acute Pain Market Insight, Epidemiology, and Market Forecast – DelveInsight”
The non-postoperative acute pain treatment market is positioned for substantial growth, driven by a strategic shift from traditional opioid therapies to advanced multimodal analgesia approaches and novel treatment options. Key pharmaceutical companies, including Vertex Pharmaceuticals, H. Lundbeck, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others, are spearheading innovation to address the significant unmet needs in non-postoperative acute pain management.

DelveInsight’s report titled “Non-Postoperative Acute Pain Market Insight, Epidemiology, and Market Forecast – 2034” provides a thorough analysis of trends in the non-postoperative acute pain market. It covers market drivers and challenges, historical and projected epidemiology, the current treatment landscape, and emerging therapies across the 7MM, which include the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The non-postoperative acute pain market size in the 7MM was valued at USD 3.6 billion in 2023, with significant growth expected at a notable CAGR during the forecast period (2024-2034). This growth is primarily fueled by rising prevalence, enhanced diagnostic capabilities, and the introduction of novel therapeutic options.

Download the Non-Postoperative Acute Pain Market Forecast Report to understand which factors are driving the Non-Postoperative Acute Pain market @ Non-Postoperative Acute Pain Market Trends.

The US represents the largest share of the non-postoperative acute pain market, with approximately 50 million incident cases reported in 2023. Epidemiological data reveal that moderate to severe cases contributed approximately 60% to the total diagnosed cases in the 7MM. Furthermore, pain cases related to migraine and cluster headaches constituted approximately 40% of total diagnosed cases in 2023 in the US, highlighting the significant burden of headache disorders within the acute pain spectrum.

Discover evolving trends in the Non-Postoperative Acute Pain patient pool forecasts @ Non-Postoperative Acute Pain Epidemiological Analysis.

The current non-postoperative acute pain treatment paradigm has undergone substantial transformation in recent years, with a notable shift away from opioid-based therapies toward multimodal analgesia (MMA) models. NSAIDs continue to play a crucial role in pain management, recognized for their ability to decrease opioid consumption by approximately 50%, positioning them as first-line medications for mild-to-moderate pain. Despite the availability of numerous generic NSAIDs following patent expirations, branded innovations continue to emerge, offering improved delivery systems and enhanced efficacy profiles.

Among the recently approved medications, ELYXYB (celecoxib) by Scilex Holding (NASDAQ: SCLX) represents a breakthrough as the first and only ready-to-use oral solution designed for fast and long-lasting migraine relief with COX-2 selectivity. Other significant market entrants include ZAVZPRET (zavegepant) by Pfizer (NYSE: PFE), the first calcitonin gene-related peptide (CGRP) receptor antagonist available as a nasal spray, and NURTEC ODT by Pfizer/Biohaven Pharmaceutical (NYSE: BHVN), expanding treatment options for patients suffering from acute migraines.

Furthermore, in January 2025, SYMBRAVO (AXS-07) was approved by the FDA for the acute treatment of migraine with or without aura in adults. The drug is a novel oral, rapidly-absorbed, multi-mechanistic investigational medicine combining MoSEIC meloxicam and rizatriptan for the acute treatment of migraine, with patent protection extending to 2036.

The non-postoperative acute pain therapeutic pipeline shows significant promise, with several advanced candidates in late-stage development. VYEPTI (eptinezumab) by H. Lundbeck A/S (CPH: HLUN-B), a monoclonal immunoglobulin G1 antibody that specifically binds to human calcitonin gene-related peptide, is currently in Phase III development for cluster headache following its FDA approval for migraine prevention in adults in February 2020.

Satsuma Pharmaceuticals (NASDAQ: STSA) is developing STS101, a dihydroergotamine nasal powder, which has demonstrated significant efficacy in providing sustained pain freedom and reduced need for rescue medication. Other notable pipeline candidates include Naltrexone Cetaminophen by Allodynic Therapeutics, further diversifying the therapeutic landscape

Discover evolving trends in the Non-Postoperative Acute Pain treatment landscape @ Non-Postoperative Acute Pain Recent Developments.

According to DelveInsight’s specialists in the field, emerging therapies like STS101 DHE nasal powder have shown significant effectiveness in providing sustained pain relief with lower rescue medication requirements. The FDA’s approval of therapies like EMGALITY for reducing the frequency of episodic cluster headache attacks represents a milestone in addressing previously undertreated acute pain conditions. These developments signal a positive trajectory for patients seeking more effective and targeted pain relief options.

Despite therapeutic advances, challenges remain in the non-postoperative acute pain landscape, including the need for improved diagnostic accuracy, personalized treatment approaches, and enhanced accessibility to innovative therapies. As the field continues to evolve, increasing focus on biomarker-guided therapy selection and integration of non-pharmacological approaches alongside pharmaceutical interventions will likely reshape treatment strategies, offering improved outcomes for the millions affected by acute pain conditions worldwide.

The integration of emerging digital health technologies and improved understanding of pain neurobiology is expected to further revolutionize acute pain management, moving toward more personalized, effective, and safer treatment paradigms that significantly enhance patient quality of life while minimizing the risks associated with traditional pain management approaches.

Table of Contents

1. Key Insights

2. Executive Summary of Non-Postoperative Acute Pain

3. Non-Postoperative Acute Pain Competitive Intelligence

4. Non-Postoperative Acute Pain: Market Overview at a Glance

5. Non-Postoperative Acute Pain: Disease Background and Overview

6. Patient Journey

7. Non-Postoperative Acute Pain Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Non-Postoperative Acute Pain Unmet Needs

10. Key Endpoints of Non-Postoperative Acute Pain Treatment

11. Non-Postoperative Acute Pain Marketed Products

12. Non-Postoperative Acute Pain Emerging Therapies

13. Non-Postoperative Acute Pain: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Non-Postoperative Acute Pain

17. KOL Views

18. Non-Postoperative Acute Pain Market Drivers

19. Non-Postoperative Acute Pain Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Postoperative Acute Pain Market Poised for Significant Expansion by 2034, Amid FDA Approvals and Innovative Therapeutic Pipeline | DelveInsight